Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The core symptoms of different dementia subtypes are the behavioral and psychological symptoms of dementia (BPSD) and its neuropsychiatric symptoms (NPS). BPSD symptoms may occur at any stage in the case of dementia due to Alzheimer's disease (AD), whereas they tend to occur early on in the case of its behavioral variant frontotemporal dementia or dementia with Lewy bodies and are essential for diagnosis. BPSD treatment consists of non-pharmacological as well as pharmacological interventions, with non-pharmacological interactions being suggested as first-line treatment. Agitation, psychotic features, apathy, depression, and anxiety may not respond to acetylcholinesterase inhibitors or memantine in AD cases; therefore, antipsychotics, antidepressants, sedative drugs or anxiolytics, and antiepileptic drugs are typically prescribed. However, such management of BPSD can be complicated by hypersensitivity to antipsychotic drugs, as observed in DLB, and a lack of effective pro-cognitive treatment in the case of frontotemporal dementia. The present paper reviews current knowledge of the management of BPSD and its limitations and discusses on-going clinical trials and future therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ohayon, M. M., Carskadon, M. A., Guilleminault, C., & Vitiello, M. V. (2004) · Sleep · doi:10.1093/sleep/27.7.1255 · Cited by 3,349
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis
Shi, L., Chen, S.-J., Ma, M.-Y., Bao, Y.-P., Han, Y., Wang, Y.-M., Shi, J., Vitiello, M. V., & Lu, L. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.06.010 · Cited by 1,009
Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy
Olazarán, J., Reisberg, B., Clare, L., Cruz, I., Peña-Casanova, J., del Ser, T., Woods, B., Beck, C., Auer, S., Lai, C., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000316119 · Cited by 937 · cited 1×
“Moreover, symptoms of depression and anxiety can be reduced by psychological interventions added to usual care (Orgeta et al., 2014; Orgeta et al., 2015).”
BackgroundZhao, Q.-F., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Xu, W., Li, J.-Q., Wang, J., Lai, T.-J., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.069 · Cited by 916
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Sleep, Cognitive impairment, and Alzheimer's disease: a systematic review and meta-analysis
Bubu, O. M., Brannick, M., Mortimer, J., Umasabor-Bubu, O., Sebastião, Y. V., Wen, Y., Schwartz, S., Borenstein, A. R., Wu, Y., Morgan, D., et al. (2017) · Sleep · doi:10.1093/sleep/zsw032 · Cited by 673
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Husebo, B. S., Ballard, C., Sandvik, R., Nilsen, O. B., & Aarsland, D. (2011) · BMJ · doi:10.1136/bmj.d4065 · Cited by 571
Depression and dementia: cause, consequence or coincidence?
Bennett, S., & Thomas, A. J. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.009 · Cited by 569
Abraha, I., Rimland, J. M., Trotta, F. M., Dell'Aquila, G., Cruz-Jentoft, A., Petrovic, M., Gudmundsson, A., Soiza, R., O'Mahony, D., Guaita, A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012759 · Cited by 557
Meta-Analysis of Nonpharmacological Interventions for Neuropsychiatric Symptoms of Dementia
Brodaty, H., & Arasaratnam, C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101529 · Cited by 479
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395 · cited 4×
“Finally, quetiapine is recommended for psychiatric symptoms in patients with dementia; this indication is covered by public insurance in Poland (Lanctôt et al., 2017).”
BackgroundInfluentialRisk of Mortality Among Individual Antipsychotics in Patients With Dementia
Kales, H. C., Kim, H. M., Zivin, K., Valenstein, M., Seyfried, L. S., Chiang, C., Cunningham, F., Schneider, L. S., & Blow, F. C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030347 · Cited by 384
Apathy in Parkinson's disease: A systematic review and meta‐analysis
den Brok, M. G. H. E., van Dalen, J. W., van Gool, W. A., Moll van Charante, E. P., de Bie, R. M. A., & Richard, E. (2015) · Movement Disorders · doi:10.1002/mds.26208 · Cited by 376
Sultzer, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., Rosenheck, R. A., Hsiao, J. K., Lieberman, J. A., Schneider, L. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111779 · Cited by 321
Antidepressants for agitation and psychosis in dementia
Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N., & Rochon, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008191.pub2 · Cited by 304
Feast, A., Moniz-Cook, E., Stoner, C., Charlesworth, G., & Orrell, M. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000922 · Cited by 290
Ismail, Z., Gatchel, J., Bateman, D. R., Barcelos-Ferreira, R., Cantillon, M., Jaeger, J., Donovan, N. J., Mortby, M. E., & Mortby, M. E. (2018) · International Psychogeriatrics · doi:10.1017/s1041610217001880 · Cited by 221 · cited 1×
“cognitive decline and dementia, biomarker of cognitive decline, or even a potential manifestation of prodromal dementia (Ismail et al., 2018; Taragano et al., 2018; Creese et al., 2019).”
BackgroundAntidepressants for treating depression in dementia
Bains, J., Birks, J., & Dening, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944 · Cited by 214
Declercq, T., Petrovic, M., Azermai, M., Vander Stichele, R., De Sutter, A. I., van Driel, M. L., & Christiaens, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007726.pub2 · Cited by 206 · cited 1×
“indicates that AD patients can be withdrawn from chronic antipsychotic medication without demonstrating detrimental effects on their behavior (Declercq et al., 2013); however, the precise effects of withdrawal on patient cognition, adverse events, quality of life, and decrease in mortality remain unknown (Van Leeuwen…”
BackgroundAntidepressants for treating depression in dementia
Dudas, R., Malouf, R., McCleery, J., & Dening, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003944.pub2 · Cited by 175
Determinants of behavioral and psychological symptoms of dementia: A scoping review of the evidence
Kolanowski, A., Boltz, M., Galik, E., Gitlin, L. N., Kales, H. C., Resnick, B., Van Haitsma, K. S., Knehans, A., Sutterlin, J. E., Sefcik, J. S., et al. (2017) · Nursing Outlook · doi:10.1016/j.outlook.2017.06.006 · Cited by 165 · cited 1×
“Pain and boredom are important determinants of agitation (Kolanowski et al., 2017), and interventions directing them have been explored as a potential way to lower the level of agitation.”
BackgroundRalph, S. J., & Espinet, A. J. (2018) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170042 · Cited by 160
Watt, J. A., Goodarzi, Z., Veroniki, A. A., Nincic, V., Khan, P. A., Ghassemi, M., Thompson, Y., Tricco, A. C., & Straus, S. E. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0993 · Cited by 159 · cited 2×
“A comparison of pharmacological and nonpharmacological interventions for treating aggression and agitation in adults with dementia (Watt et al., 2019) found showed that multidisciplinary care, massage and touch therapy, and music combined with massage and touch therapy were clinically more efficacious than usual care.”
BackgroundWang, Y.-C., Tai, P.-A., Poly, T. N., Islam, M. M., Yang, H.-C., Wu, C.-C., & Li, Y.-C. (. (2018) · Behavioural Neurology · doi:10.1155/2018/5315098 · Cited by 115
Antipsychotic Use in Dementia: Is There a Problem and Are There Solutions?
Kirkham, J., Sherman, C., Velkers, C., Maxwell, C., Gill, S., Rochon, P., & Seitz, D. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716673321 · Cited by 113 · cited 1×
“, 2017), and some measures for limiting such practices have been undertaken (Jessop et al., 2017; Kirkham et al., 2017).”
BackgroundPharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113
Moraros, J., Nwankwo, C., Patten, S. B., & Mousseau, D. D. (2017) · Depression and Anxiety · doi:10.1002/da.22584 · Cited by 105
What Behavioral and Psychological Symptoms of Dementia Affect Caregiver Burnout?
Hiyoshi-Taniguchi, K., Becker, C. B., & Kinoshita, A. (2018) · Clinical Gerontologist · doi:10.1080/07317115.2017.1398797 · Cited by 81
Sleep Disturbances in Frontotemporal Dementia
McCarter, S. J., St. Louis, E. K., & Boeve, B. F. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0680-3 · Cited by 80 · cited 1×
“Similarly, those observed in FTDs include insomnia, excessive daytime sleepiness, sleep disordered breathing, and less frequent restless leg syndrome (McCarter et al., 2016).”
BackgroundKobayashi, H., Ohnishi, T., Nakagawa, R., & Yoshizawa, K. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4405 · Cited by 79
Hilgeman, M. M., Allen, R. S., Snow, A. L., Durkin, D. W., DeCoster, J., & Burgio, L. (2014) · Aging & Mental Health · doi:10.1080/13607863.2013.868403 · Cited by 77 · cited 1×
“After intervention, authors observed lower depressive symptoms and illness burden and greater quality of life and health-related indicators of well-being (Hilgeman et al., 2014).”
BackgroundDementia severity and the longitudinal costs of informal care in the Cache County population
Rattinger, G. B., Schwartz, S., Mullins, C. D., Corcoran, C., Zuckerman, I. H., Sanders, C., Norton, M. C., Fauth, E. B., Leoutsakos, J. S., Lyketsos, C. G., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.004 · Cited by 71
Apathy: A neurocircuitry model based on frontotemporal dementia
Ducharme, S., Price, B. H., & Dickerson, B. C. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316277 · Cited by 69 · cited 1×
“Although our understanding of the underlying neuronal basis of apathy has improved in recent years, the effectiveness of treatment is still limited (Huey et al., 2017; Lansdall et al., 2017; Ducharme et al., 2018; Fernández-Matarrubia et al., 2018; Kumfor et al., 2018).”
BackgroundHorr, T., Messinger-Rapport, B., & Pillai, J. A. (2015) · The Journal of nutrition, health and aging · doi:10.1007/s12603-014-0565-6 · Cited by 67 · cited 1×
“As recent papers on non-pharmacological interventions have higher reporting quality than older ones, it is likely that our knowledge on the role of non-pharmacological interventions will be steadily improved as more studies are performed (Horr et al., 2015).”
Yury, C. A., & Fisher, J. E. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000101499 · Cited by 63 · cited 1×
“org 2 pharmacological strategies were even found to be more effective than pharmacological treatments (Yury and Fisher, 2007; Brodaty and Arasaratnam, 2012; Schneider et al., 2006a) and appear to have fewer adverse effects than pharmacotherapy with antipsychotics (Dyer et al.”
BackgroundAntidepressant Treatment and Risk of Dementia: A Population-Based, Retrospective Case-Control Study
Lee, C. W.-S., Lin, C.-L., Sung, F.-C., Liang, J.-A., & Kao, C.-H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09580 · Cited by 61
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease
Trzepacz, P. T., Cummings, J., Konechnik, T., Forrester, T. D., Chang, C., Dennehy, E. B., Willis, B. A., Shuler, C., Tabas, L. B., & Lyketsos, C. (2013) · International Psychogeriatrics · doi:10.1017/s1041610212002141 · Cited by 53
Persistence of and Changes in Neuropsychiatric Symptoms in Alzheimer Disease Over 6 Months
Ryu, S.-H., Katona, C., Rive, B., & Livingston, G. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200511000-00008 · Cited by 22
Sugawara Kikuchi, Y., & Shimizu, T. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189050 · Cited by 14
Cited by
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
“New pharmacotherapeutics for agitation and psychosis associated with AD, such as pimavanserin, scyllo-inositol, and mibampator, are in clinical trials [27].”
BackgroundPhysician-Assisted Suicide in Dementia: Paradoxes, Pitfalls and the Need for Prudence
Rajkumar, R. P. (2021) · Frontiers in Sociology · doi:10.3389/fsoc.2021.815233 · Cited by 11
“, 2021); novel therapeutic strategies are being developed and evaluated (Magierski et al., 2020); and in some cases, nonpharmacological strategies may also be safe and effective (Abraha et al.”
BackgroundDi Passa, A.-M., Dabir, M., Fein, A., Khoshroo, S., McIntyre-Wood, C., Marsden, E., MacKillop, E., De Jesus, J., MacKillop, J., & Duarte, D. (2023) · JMIR Research Protocols · doi:10.2196/45213 · Cited by 2
Metadata
- Authors
- Magierski, R., Sobow, T., Schwertner, E., & Religa, D.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-31
- Volume
- 11
- Pages
- 1168-1168
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3046571429
- Cited by
- 118
- References
- 43
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.